James W. Traweek Jr. is 10% Owner at REATA PHARMACEUTICALS INC (RETA). They have made 20 open-market trades across 1 company since 2016, most recently 2020-01-02.
CIK 0001358762
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
20 open-market purchases totalling $103.5M since 2016, never a sale. Across 20 scored buys the stock is up 24.5% at ninety days, and 22.2 points ahead of the S&P over the same stretch.
20 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 70% | 70% |
| Avg Move | +6.5% | +19.8% | +24.5% |
| Alpha | +6.8% | +18.9% | +22.2% |
| Scored | 20 | 20 | 20 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RETA | BUY | 2019-11-18 | 2019-11-18 | $183.00 | $7.4M | -7.1% | +1.5% | +8.6% |
| RETA | BUY | 2018-12-10 | 2018-12-12 | $59.41 | $13.2M | -22.1% | +15.6% | +51.6% |
| RETA | BUY | 2017-12-29 | 2017-12-29 | $28.47 | $484K | +0.0% | +3.6% | -27.5% |
| RETA | BUY | 2017-12-26 | 2017-12-28 | $25.93 | $705K | +5.8% | +7.5% | -26.7% |
| RETA | BUY | 2017-12-13 | 2017-12-15 | $24.75 | $6.9M | +4.7% | +11.9% | -10.8% |
| RETA | BUY | 2017-06-22 | 2017-06-23 | $25.00 | $30.0M | +8.6% | +21.8% | +8.6% |
| RETA | BUY | 2016-12-30 | 2017-01-04 | $21.72 | $408K | -4.5% | -0.1% | -2.8% |
| RETA | BUY | 2016-12-16 | 2016-12-20 | $22.99 | $7.6M | -5.5% | +0.2% | +19.2% |
| RETA | BUY | 2016-12-14 | 2016-12-16 | $21.49 | $324K | -5.9% | -4.4% | +17.8% |
| RETA | BUY | 2016-08-18 | 2016-08-18 | $17.32 | $1.8M | +7.0% | +68.0% | +77.1% |
| RETA | BUY | 2016-08-17 | 2016-08-18 | $17.26 | $2.5M | +7.0% | +68.0% | +77.1% |
| RETA | BUY | 2016-08-16 | 2016-08-18 | $17.17 | $9.6M | +7.0% | +68.0% | +77.1% |
| RETA | BUY | 2016-08-16 | 2016-08-18 | $16.21 | $950K | +7.0% | +68.0% | +77.1% |
| RETA | BUY | 2016-06-28 | 2016-06-30 | $19.78 | $3.3M | -13.4% | -20.1% | +24.2% |
| RETA | BUY | 2016-06-24 | 2016-06-28 | $19.26 | $2.8M | -21.3% | -21.5% | +12.6% |
| RETA | BUY | 2016-06-06 | 2016-06-08 | $17.58 | $500K | -18.1% | -20.1% | -3.0% |
| RETA | BUY | 2016-06-01 | 2016-06-01 | $12.68 | $3.1M | +72.9% | +38.2% | +32.4% |
| RETA | BUY | 2016-06-01 | 2016-06-01 | $12.70 | $3.2M | +72.9% | +38.2% | +32.4% |
| RETA | BUY | 2016-06-01 | 2016-08-09 | $11.00 | $8.8M | +13.9% | +60.0% | +46.2% |
| RETA | BUY | 2016-06-01 | 2016-06-03 | $13.42 | $108K | +20.7% | -7.7% | -1.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.